Mystic Pharmaceuticals Receives Qualifying Therapeutic Discovery Grant for Drug Delivery Technology

Published: Nov 08, 2010

AUSTIN, Texas--(BUSINESS WIRE)--Mystic Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of advanced precision ophthalmic and intranasal delivery technologies for drugs and biologics, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to its VersiDoserâ„¢ Delivery Platform under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

Back to news